Cardioneuroablation vs Pulmonary Vein Isolation in Treatment of Paroxysmal Atrial Fibrillation

Atrial Fibrillation Paroxysmal Clinical Trial

Official title:

Cardioneuroablation of Right Anterior Ganglionated Plexus vs Pulmonary Vein Isolation in Patients With Paroxysmal Atrial Fibrillation and Enhanced Vagal Tone

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06058468
• Other study ID #: 2022/084/W
• Status: Not yet recruiting
• Phase: N/A
• Start date: January 2024
• Est. completion date: June 2029

Study information

• Verified date: September 2023
• Source: St. Joseph's Centre, Poland
• Contact: Piotr Futyma
• Phone: +48 533 503 044
• Email: piotr.futyma[@]gmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this study is to compare effectiveness of cardioneuroablation of right anterior ganglionated plexus and pulmonary vein isolation in patients with enhanced vagal tone expressed as deceleration capacity >7.5ms.

Description:

Patients included into the study will be randomized to a group undergoing cardioneuroablation (CNA) of the right anterior ganglionated plexus (RAGP) or pulmonary vein isolation (PVI). In CNA group the location of RAGP will be determined anatomically below the superior vena cava ostium near the superior-septal aspect of the right atrium. Radiofrequency (RF) applications will be delivered and will be continued until heart rate (HR) acceleration >30% is achieved or if the RF time exceeds 120s. In the PVI group point-by-point RF isolation of all pulmonary veins will be performed. Clinical follow-up (FU) will consist of multiple ambulatory visits combined with standard ECG readings and a 7-day Holter recording. During FU visits, a detailed history of any palpitations, episodes of atrial fibrillation (AF), and hospitalizations for cardiac arrhythmias will be collected.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 160
• Est. completion date: June 2029
• Est. primary completion date: January 2028
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Paroxysmal atrial fibrillation documented in ECG or Holter monitoring
• Deceleration capacity >7.5ms
• Life expectancy more than 1 year
• Age =18 years

Exclusion Criteria:

• Permanent AF lasting more than one year or persistent AF lasting more than 7 days
• AF secondary to electrolyte imbalance, thyroid disease, alcohol abuse, or other non-heart related causes
• Anteroposterior dimension of the left atrium in the echocardiography =43mm
• Clinically significant arrhythmias other than AF
• Significant valvular disease
• Valve prosthesis
• Heart failure III or IV Class in New York Heart Association Classification
• Previous ablation of atrial fibrillation or atrial flutter
• History of a patent foramen ovale/atrial septal defect closure
• History of left atrial appendage closure
• Atrial myxoma
• Presence of a cardiac pacemaker, defibrillator or cardiac resynchronization therapy device
• History of pericarditis
• Congenital heart disease
• History of bleeding or coagulation disorders
• Contraindications to oral anticoagulation
• Contraindications to computed tomography or magnetic resonance imaging
• Pregnancy or breast-feeding
• BMI>31
• History of transplantation
• Severe lung disease
• Chronic renal failure defined as estimated glomerular filtration rate (eGFR) <30 mL/min/m2
• Cancer
• Significant infection
• Life expectancy less than one year
• Mental disorders
• Lack of informed consent to participate in the trial

Related Conditions & MeSH terms

• Atrial Fibrillation
• Atrial Fibrillation Paroxysmal

Intervention

Procedure:
• Cardioneuroablation of right anterior ganglionated plexus
Right anterior ganglionated plexus will be localized using anatomical approach. Radiofrequency energy will be delivered until heart rate acceleration >30% is achieved or if radiofrequency time exceeds 120 seconds.
• Pulmonary vein isolation
Application sites near the ostia of pulmonary veins will be determined. Radiofrequency energy will be delivered using point-by-point technique. After applications, the acute PVI endpoint will be confirmed by the elimination of PV potentials and lack of capture during pacing from the ablation lines.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
St. Joseph's Centre, Poland

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	AF recurrence	AF episode lasting 30 seconds or more, documented on 12-lead ECG, event or Holter monitoring	1 year